An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid

Trial Profile

An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Pegadricase (Primary) ; SEL 212 (Primary) ; Sirolimus (Primary)
  • Indications Gout
  • Focus Adverse reactions
  • Sponsors Selecta Biosciences
  • Most Recent Events

    • 10 Apr 2018 According to a Selecta Biosciences media release, the company plans to present data from patients receiving five monthly SEL-212 doses at an upcoming medical meeting in the third quarter 2018.
    • 10 Apr 2018 Results published in the Selecta Biosciences Media Release
    • 10 Apr 2018 According to a Selecta Biosciences media release, new data from this trial presented at the Pan American League of Associations for Rheumatology (PANLAR) 2018 Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top